Here's why I can't wait to buy Chemist Warehouse shares

Chemist Warehouse would tick all my boxes for a great investment.

| More on:
Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One of the biggest pieces of ASX news this week was the revelation that Chemist Warehouse shares might, at long last, be coming to the Australian stock market.

As we covered earlier this week, rumours are abounding that Chemist Warehouse might make its long-awaited ASX debut through some kind of 'reverse-merger' with ASX 300 healthcare stock Sigma Healthcare Ltd (ASX: SIG).

Sigma shares were quickly halted from trading amid these rumours, with the company confirming that "an announcement relating to a potential material transaction" is on the way. The shares have reportedly been halted until at least next week to "ensure the market is not trading on an uninformed basis while those discussions are ongoing".

So we don't yet know if Chemist Warehouse is indeed coming to the public markets. But I'm excited anyway. That's because Chemist Warehouse — if it does eventually list on the ASX — is a company that ticks almost all of my boxes as a potential investment.

Why am I keen to buy Chemist Warehouse shares?

Chances are most of us have visited a Chemist Warehouse somewhat recently. After all, this is a pharmacy chain that, according to a recent analysis from EY, "now commands over 50% market share in Australia".

Chemist Warehouse (at least in its current form) was founded back in 1993. So this is quite an accomplishment. Its controversial (yet evidently lucrative) business strategy of sidestepping Australia's strict pharmaceutical regulations that limit pharmacy proliferation has proved to be a winner.

My favourite investments usually have at least some of the following characteristics

  • a market leader in its industry
  • indication of the presence of a strong economic moat
  • operating in a defensive sector that is resistant to recessions and inflation

Chemist Warehouse seems to tick all three boxes.

It's clear that the company commands a leading position in the pharmaceutical industry if EY's analysis is to be believed.

Chemist Warehouse has strong brand power, as well as an obvious pricing advantage. Both of these moats have arguably allowed the company to expand at the expense of competitors.

And pharmaceuticals and medicines are highly defensive markets. When most of us are sick, we buy the medicines and pharmaceuticals that help us ride it out, regardless of economic conditions.

Private companies and public knowledge

Of course, I'll be doing some due diligence before I actually pick up the shares. Even now, Chemist Warehouse remains a private company. This means that details such as internal operations, financials and other information that public companies have to disclose remain unavailable to the public.

I'll want to get a good look at this information before buying up shares. I'll also want to buy the company at a price that makes sense. Not on whatever it trades at when it first lists.

But even so, I'll be excited to pick up some shares if and when the company eventually joins the ASX. Provided there are no red flags, of course.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a young scientist using a digital tablet while working in a lab.
52-Week Highs

Medibank share price hits 52-week high on US tech partnership

This private health insurer's shares are scaling new heights today. But why?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

What is the dividend growth rate of CSL stock?

CSL's dividends are worth more than what meets the eye.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Earnings Results

Sonic share price sinks after first-half profit crash

The healthcare company's profits have almost halved.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

The market is placing 'zero value' on this ASX 200 stock's booming pipeline

Up 78% in a year, these experts reckon there’s more outperformance to come from this top ASX 200 stock.

Read more »

Shot of a senior scientist looking stressed out while working in a lab.
Healthcare Shares

This ASX 200 healthcare share is diving 13% as short sellers take aim

A short seller is describing this company's Daybue product as a 'flop'.

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Healthcare Shares

Guess which ASX 300 healthcare stock is surging 13% on FDA news

Here's what's getting investors excited today.

Read more »

an angry man in a suit stands with his hands outstretched in a questioning gesture of annoyance and displeasure while an airport check in attendant is on the telephone in the background.
Earnings Results

This ASX 200 healthcare stock is sinking 6% despite explosive first-half earnings growth

Sometimes the market just expects too much from companies.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

2 ASX healthcare shares with 'compelling' valuations to buy

The QVE team reckons this pair of small caps can be bought for cheap right now, but could rocket very…

Read more »